| Literature DB >> 28462920 |
S M Baxi1,2, R M Greenblatt1,3,4, P Bacchetti4, M Cohen5, J A DeHovitz6, K Anastos7, S J Gange8, M A Young9, B E Aouizerat3,10,11.
Abstract
Higher exposure to tenofovir (TFV) increases the risk for kidney function decline, but the impact of genetic factors on TFV exposure is largely unknown. We investigated whether single-nucleotide polymorphisms (SNPs, n=211) in 12 genes are potentially involved in TFV exposure. Participants (n=91) from the Women's Interagency HIV Study, underwent a 24 h intensive pharmacokinetic sampling of TFV after witnessed dose and TFV area under the time-concentration curves (AUCs) were calculated for each participant. SNPs were assayed using a combination of array genotyping and Sanger sequencing. Linear regression models were applied to logarithmically transformed AUC. Those SNPs that met an a priori threshold of P<0.001 were considered statistically associated with TFV AUC. ABCG2 SNP rs2231142 was associated with TFV AUC with rare allele carriers displaying 1.51-fold increase in TFV AUC (95% confidence interval: 1.26, 1.81; P=1.7 × 10-5). We present evidence of a moderately strong effect of the rs2231142 SNP in ABCG2 on a 24 h TFV AUC.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28462920 DOI: 10.1038/tpj.2017.3
Source DB: PubMed Journal: Pharmacogenomics J ISSN: 1470-269X Impact factor: 3.550